Entry Detail
| General information | |
| Database: | DB01022 |
| Objective: | To determine the effect of imatinib on progression free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). |
| Authors: | Juretzka M, et al |
| Title: | a phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. |
| Journal: | Eur J Gynaecol Oncol. |
| Year: | 2008 |
| PMID: | 19115680 |
| Trial Design | |
| Clinical Trial Id: | NA |
| Agent: | imatinib mesylate |
| Target: | Abl Plateletderived growth factor receptor Mast/stem cell growth factor receptor |
| Cancer Type: | ovarian, primary peritoneal, or fallopian tube carcinoma |
| Cancer Subtype: | epithelial ovarian, primary peritoneal, or fallopian tube carcinoma |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | a phase II trial |
| Key Patients Feature: | patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission |
| Biomarker: | PDGFR staining |
| Biomark Analysis: | No associations were seen between PDGFR staining and PFS. |
| Control Group Info: | single arm |
| Treatment Info: | Eligible patients received imatinib at 400 mg daily orally. |
| Primary End Point: | PFS |
| Secondary End Point: | NA |
| Patients Number: | 35 |
| Trial Results | |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | NA |
| Conclusions: | Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate. |